Header

Pediatric Solid Tumors Clinical Trials

Category:Pediatric
Status:Active

Displaying all 19 trials

Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer

This phase III trial studies the side effects and how well risk-based therapy works in treating younger patients with newly diagnosed liver cancer. Surgery, chemotherapy drugs (cancer fighting medi...

Diagnosis: Pediatric Solid Tumors

Phase: 3

Protocol Number: 09-379

Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors

This randomized phase III trial studies how well standard-dose combination chemotherapy works compared to high-dose combination chemotherapy and stem cell transplant in treating patients with germ ...

Diagnosis: Pediatric Solid Tumors, Other Cancers

Phase: 3

Protocol Number: 16-701

Study of Selinexor in Pediatric Solid Tumors

The investigators will conduct a phase 1 trial of Selinexor in children with recurrent or refractory solid tumors, including CNS tumors using the Rolling Six design. The aims of the trial will be t...

Diagnosis: Pediatric Solid Tumors

Phase: 1

Protocol Number: 15-718

Oral TRK Inhibitor LOXO-101 for Treatment of Advanced Pediatric Solid or Primary Central Nervous System Tumors

This is a multicenter, open-label, Phase 1 study in pediatric patients with advanced solid or primary CNS tumors. LOXO‑101 will be administered orally (PO) twice daily (BID), with the dose adjusted...

Diagnosis: Pediatric Oncology, Pediatric Solid Tumors

Phase: 1

Protocol Number: 16-094

Study of RXDX-101 in Children With Recurrent or Refractory Solid Tumors and Primary CNS Tumors

This is a 4-part, open-label, Phase 1/1b, dose escalation study in pediatric patients with relapsed refractory solid tumors; 2) primary CNS tumors; 3) neuroblastoma; and 4) non-neuroblastoma, extra...

Diagnosis: Pediatric Solid Tumors

Phase: 1

Protocol Number: 16-045

Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma

This research study is evaluating a novel drug called CUDC-907 as a possible treatment for resistant (refractory) pediatric solid tumors (including neuroblastoma), lymphoma, or brain tumors.

Diagnosis: Pediatric Solid Tumors, Pediatric Lymphoma

Phase: 1

Protocol Number: 16-371

A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer

The main purpose of this study is to evaluate the safety of different doses of olaratumab and to determine which dose should be used for future pediatric studies. The present study is open to child...

Diagnosis: Pediatric Brain Tumor, Pediatric Solid Tumors, Pediatric Sarcoma, Pediatric Neuroblastoma

Phase: 1

Protocol Number: 16-196

Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer

This study is collecting and storing malignant, borderline malignant neoplasms, and related biological samples from young patients with cancer. Collecting and storing samples of tumor tissue, blood...

Diagnosis: Pediatric Solid Tumors

Phase: N/A

Protocol Number:

The iCat2, GAIN Consortium Study

This research study is evaluating the use of specialized testing of solid tumors including sequencing. The process of performing these specialized tests is called tumor profiling. The tumor profili...

Diagnosis: Pediatric Solid Tumors

Phase: N/A

Protocol Number: 15-169

A Study to Determine Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib In Children and Adolescent Subjects

This is a 2-part, study to determine the safety, tolerability and pharmacokinetics of oral dabrafenib in children and adolescent subjects with advanced BRAF V600 mutation-positive solid tumors. Par...

Diagnosis: Pediatric Solid Tumors, Pediatric Brain Tumor

Phase:

Protocol Number: 12-429

Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations

This is a 3-part (Part A, Part B, Part C), Phase I/IIa, multi-center, open label, study in pediatric subjects with refractory or recurrent tumors. Part A is a repeat dose, dose escalation monothera...

Diagnosis: Pediatric Solid Tumors

Phase:

Protocol Number: 15-079

A Single-Arm Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of MPDL3280A (Anti-PD-L1 Antibody) in Pediatric and Young Adult Participants With Solid Tumors

This early phase, multicenter, open-label, single-arm study will evaluate the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary efficacy of MPDL3280A in pediatric and young ad...

Diagnosis: Pediatric Solid Tumors, Pediatric Oncology

Phase:

Protocol Number: 15-308

Phase I Trial of Afatinib in Pediatric Tumours

Open-label, dose escalation, monotherapy, basket trial with biomarker specific MTD expansion cohort The trial will consist of 2 parts: 1. Dose finding part to determine the MTD 2. Biomarker specifi...

Diagnosis: Pediatric Solid Tumors

Phase:

Protocol Number: 15-315

iMATRIXcobi: Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Patients With Previously Treated Solid Tumors

This open-label, dose-escalation study is designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of cobimetinib in pediatric and young adult participants with sol...

Diagnosis: Pediatric Solid Tumors

Phase:

Protocol Number: 15-524

A Study of Pembrolizumab (MK-3475) in Pediatric Participants With Advanced Melanoma or Advanced, Relapsed, or Refractory PD-L1-Positive Solid Tumors or Lymphoma (MK-3475-051/KEYNOTE-051)

This is a 2-part study of pembrolizumab (MK-3475) in pediatric participants who have either advanced melanoma or a programmed cell death ligand 1 (PD-L1)-positive advanced, relapsed or refractory s...

Diagnosis: Pediatric Solid Tumors, Pediatric Hematology/Blood Related

Phase:

Protocol Number: 16-235

WEE1 Inhibitor MK-1775 and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors

This phase I/II trial studies the side effects and best dose of WEE1 inhibitor MK-1775 and irinotecan hydrochloride in treating younger patients with solid tumors that have come back or that have n...

Diagnosis: Pediatric Solid Tumors, Pediatric Brain Tumor

Phase:

Protocol Number: 16-447

Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors

This phase I trial studies the side effects and best dose of entinostat in treating pediatric patients with solid tumors that have come back or have not responded to treatment. Entinostat may block...

Diagnosis: Pediatric Solid Tumors

Phase:

Protocol Number: 17-700

Crizotinib (Xalkori) Expanded Access Protocol For The Treatment Of Adult Or Pediatric Patients

This is an open label expanded access protocol for the treatment of up to approximately 40 adult or pediatric (defined as age <18 years) patients with tumors harboring either a chromosomal trans...

Diagnosis: Pediatric Hematology/Blood Related, Pediatric Solid Tumors, Solid Tumor/Phase I

Phase:

Protocol Number: 16-555

Identification of Biomarkers for Patients With Vascular Anomalies

The study will use participants tissue previously collected and stored in a tissue bank maintained by the Department of Hematology/Oncology as well as tissue banked in the future from participants ...

Diagnosis: Pediatric Solid Tumors, Pediatric Sarcoma

Phase:

Protocol Number:

'